List of Latuda drug patents
Latuda is owned by Sunovion Pharms Inc.
Latuda contains Lurasidone Hydrochloride.
Latuda has a total of 14 drug patents out of which 0 drug patents have expired.
Latuda was authorised for market use on 28 October, 2010.
Latuda is available in tablet;oral dosage forms.
Latuda can be used as treatment of schizophrenia with improvement in attention function in schizophrenia; treatment of bipolar depression with improvement in attention function in bipolar disorder, treatment of schizophrenia, treatment of schizophrenia or bipolar depression with improvement in attention function in schizophrenia and/or bipolar disorder, treatment of schizophrenia with improvement in negative symptoms and/or cognitive dysfunction of schizophrenia, treatment of major depressive episodes associated with bipolar i disorder; treatment of schizophrenia.
The generics of Latuda are possible to be released after 23 November, 2031.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| USRE45573 | SUNOVION PHARMS INC | Process for producing imide compound |
Jun, 2025
(2 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9815827 | SUNOVION PHARMS INC | Agent for treatment of schizophrenia |
Feb, 2024
(1 year, 10 days from now) | |
| US9174975 | SUNOVION PHARMS INC | Remedy for integration dysfunction syndrome |
Feb, 2024
(1 year, 10 days from now) | |
|
US9174975
(Pediatric) | SUNOVION PHARMS INC | Remedy for integration dysfunction syndrome |
Aug, 2024
(1 year, 6 months from now) | |
|
USRE45573
(Pediatric) | SUNOVION PHARMS INC | Process for producing imide compound |
Dec, 2025
(2 years from now) | |
| US8729085 | SUNOVION PHARMS INC | Pharmaceutical composition |
May, 2026
(3 years from now) | |
| US9555027 | SUNOVION PHARMS INC | Pharmaceutical composition |
May, 2026
(3 years from now) | |
| US9907794 | SUNOVION PHARMS INC | Pharmaceutical composition |
May, 2026
(3 years from now) | |
| US8883794 | SUNOVION PHARMS INC | Pharmaceutical composition |
May, 2026
(3 years from now) | |
|
US8883794
(Pediatric) | SUNOVION PHARMS INC | Pharmaceutical composition |
Nov, 2026
(3 years from now) | |
|
US8729085
(Pediatric) | SUNOVION PHARMS INC | Pharmaceutical composition |
Nov, 2026
(3 years from now) | |
| US9259423 | SUNOVION PHARMS INC | Method of treatment for mental disorders |
May, 2031
(8 years from now) | |
| US9827242 | SUNOVION PHARMS INC | Method of treatment for mental disorders |
May, 2031
(8 years from now) | |
|
US9259423
(Pediatric) | SUNOVION PHARMS INC | Method of treatment for mental disorders |
Nov, 2031
(8 years from now) | |
Drugs and Companies using LURASIDONE HYDROCHLORIDE ingredient
Market Authorisation Date: 28 October, 2010
Treatment: Treatment of major depressive episodes associated with bipolar i disorder; Treatment of schizophrenia; Treatment of schizophrenia with improvement in negative symptoms and/or cognitive dysfunction of schizophrenia; Treatment of schizophrenia or bipolar depression with improvement in attention function in schizophrenia and/or bipolar disorder; Treatment of schizophrenia with improvement in attention function in schizophrenia; Treatment of bipolar depression with improvement in attention function in bipolar disorder
Dosage: TABLET;ORAL
LATUDA family patents
16
United States
11
Japan
6
European Union
4
Spain
3
China
2
Korea, Republic of
2
Brazil
2
Australia
2
Canada
2
Denmark
1
Austria
1
Hong Kong
1
Poland
1
Luxembourg
1
Netherlands
1
Germany
1
Cyprus
1
Mexico
1
Slovenia
1
Hungary
1
Portugal
1
Russia
1
Taiwan, Province of China
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic